Key Analyst Estimates
Astrazeneca (AZN) is expected to report quarterly earnings of $0.95 per share, according to Wall Street analysts. This represents a 1% decline compared to the same period last year. Revenues are forecasted to be $11.94 billion, a 9.7% increase year-over-year.
Analysts have revised their earnings estimates downwards by 1.7% in the past 30 days. This indicates a shift in their expectations for the company's performance.
Product Sales- CVRM- Brilinta: Estimated at $310.25 million, a 7.1% decrease year-over-year.
Estimated at $49.01 million, a 22.2% decrease year-over-year.
Estimated at $1.62 billion, a 24.9% increase year-over-year.
Estimated at $724.52 million, an 11.3% increase year-over-year.
Estimated at $227.69 million, a 13.3% increase year-over-year.
Estimated at $167.43 million, a 6.5% decrease year-over-year.
Estimated at $6.32 million, a 54.8% decrease year-over-year.
Estimated at $302.51 million, a 12.9% increase year-over-year.
Estimated at $635.60 million, a 21.8% increase year-over-year.
Estimated at $442.60 million, a 15.3% increase year-over-year.
Estimated at $400.36 million, a 35.3% increase year-over-year.
Estimated at $64.23 million, a 14.7% increase year-over-year.
Astrazeneca shares have outperformed the market in the past month, with a return of +3.5% compared to the Zacks S&P 500 composite's -4% change. The company has a Zacks Rank #3 (Hold), indicating that its performance is expected to be in line with the overall market in the near future.